Extended-spectrum beta-lactamases (ESBLs) detection in some uropathogenic bacteria and their correlation with biofilm formation
Background and objective: The tolerance of biofilms to antibiotics results in the dissemination of resistance. Many of the recurrent urinary tract infections are assumed to be caused by biofilm producing uropathogenic isolates. This study aimed to investigate the correlation between the ability of biofilm formation and extended spectrum beta lactamase producing uropathogens.
Methods: A total of 438 urine specimens were collected from Rizgary Teaching hospital in Erbil, Iraq, from September to December 2017. Extended spectrum beta lactamase was determined using the Vitek-2 automated system and confirmed by using the combination disk diffusion test. Biofilm formation was checked using 96-well flat bottom microtiter plates.
Results: Out of the 438 urine specimens, only 37.89% (n =166) developed an infection, the most common isolate was Escherichia coli. The distribution of the bacterial species according to the patients' gender found to be significant (P = 0.014). The proportion of betalactamase producing isolates was 29% (n = 31). The strength of biofilm formation among Klebsiella species was significantly higher than in Escherichia coli (P <0.001), while a non-significant difference (P = 0.163) was observed between beta lactamase production and ability of biofilm formation. The sensitivity and specificity of VITEK-2 in the detection of extended-spectrum beta-lactamase were 79.48% and 80.95%, respectively.
Conclusion: The study revealed that Klebsiellae species were stronger biofilm producers. Beta lactamase producing isolates do not have a greater ability of biofilm formation.
Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183(Supplement_1):S1–4.
Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin 2014; 28(1): 1–13.
Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010; 7(12):653.
Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria—Time to react is now. Drug Resist Updat 2011; 14(2):118–24.
Shrivastava SR, Shrivastava PS, Ramasamy J. World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Journal of Medical Society 2018; 32(1):76-7.
Ruppé E, Hem S, Lath S, Gautier V, Ariey F, Sarthou J-L, et al. CTX-M β-lactamases in Escherichia coli from community-acquired urinary tract infections, Cambodia. Emerg Infect Dis 2009; 15(5):741
Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol 2005; 13(1):34–40.
Tezel BU, Akçelik N, Yüksel FN, Karatuğ NT, Akçelik M. Effects of sub-MIC antibiotic concentrations on biofilm production of Salmonella Infantis. Biotechnol Biotechnol Equip 2016; 30(6):1184–91
Poovendran P, Vidhya N, Murugan S. Antimicrobial activity of Coccinia grandis against biofilm and ESBL producing uropathogenic E. coli. Glob J Pharmacol 2011; 5(1):23–6.
Allan RN, Morgan S, Brito-Mutunayagam S, Skipp P, Feelisch M, Hayes SM, et al. Low concentrations of nitric oxide modulate Streptococcus pneumoniae biofilm metabolism and antibiotic tolerance. Antimicrob Agents Chemother 2016; 60(4):2456–66.
Rijavec M, Müller-Premru M, Zakotnik B, Žgur-Bertok D. Virulence factors and biofilm production among Escherichia coli strains causing bacteraemia of urinary tract origin. J Med Microbiol 2008; 57(11):1329–34.
Heydari S, Eftekhar F. Biofilm formation and β-lactamase production in burn isolates of Pseudomonas aeruginosa. Jundishapur J Microbiol 2015; 8(3).
Rao RS, Karthika RU, Singh SP, Shashikala P, Kanungo R, Jayachandran S, et al. Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii. Indian J Med Microbiol 2008; 26(4):333.
Neupane S, Pant ND, Khatiwada S, Chaudhary R, Banjara MR. Correlation between biofilm formation and resistance toward different commonly used antibiotics along with extended spectrum beta lactamase production in uropathogenic Escherichia coli isolated from the patients suspected of urinary tract infections visiting Shree Birendra Hospital, Chhauni, Kathmandu, Nepal. Antimicrob Resist Infect Control 2016; 5(1):5.
Dieter RS. Sterile pyuria: a differential diagnosis. Compr Ther 2000; 26(3):150–2.
Stepanović S, Vuković D, Dakić I, Savić B, Švabić-Vlahović M. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 2000; 40(2):175–9.
Eliopoulos GM, Bush K. New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32(7):1085–9.
Livermore DM, Struelens M, Amorim J, Baquero F, Bille J, Canton R, et al. Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. J Antimicrob Chemother 2002; 49(2):289–300.
Linscott AJ, Brown WJ. Evaluation of four commercially available extended-spectrum beta-lactamase phenotypic confirmation tests. J Clin Microbiol 2005; 43(3):1081–5.
Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eurosurveillance 2008; 13(47):19044.
Poovendran P, Vidhya N, Murugan S. Antimicrobial susceptibility pattern of ESBL and non-ESBL producing uropathogenic Escherichia coli (UPEC) and their correlation with biofilm formation. Int J Microbiol Res 2013; 4(1):56–63.
Tadepalli S, Prudhivi S, Babu Myneni R, Rao S. Biofilm formation in uropathogenic Escherichia coli isolates and its association with extended spectrum betalactamase production and drug resistance. Saudi J Pathol Microbiol 2016; 1:260–4.
Shanmugam K, Thyagarajan R, Katragadda R, Vajravelu L, Jayachandran AL. Biofilm formation and Extended Spectrum Beta Lactamases (ESBL) producers among the gram negative bacteria causing Urinary tract infections. Int J Med Microbiol Trop Dis 2017; 3(3):86–90.
Yılmaz ES, Güvensen NC. In vitro biofilm formation in ESBL producing Escherichia coli isolates from cage birds. Asian Pac J Trop Med 2016; 9(11):1069–74.
Yang D, Zhang Z. Biofilm-forming Klebsiella pneumoniae strains have greater likelihood of producing extended-spectrum β-lactamases. J Hosp Infect 2008; 68(4):369–71.
Schroll C, Barken KB, Krogfelt KA, Struve C. Role of type 1 and type 3 fimbriae in Klebsiella pneumoniae biofilm formation. BMC Microbiol 2010; 10(1):179.
Alberici I, Bayazit AK, Drozdz D, Emre S, Fischbach M, Harambat J, et al. Pathogens causing urinary tract infections in infants: a European overview by the ESCAPE study group. Eur J Pediatr 2015; 174(6):783–90.
Alsamarai AGM, Ali S. Urinary tract infection in Female in Kirkuk city, Iraq: Causative agents and antibiogram. WJPPS 2016; 5:261–73.
Edlin RS, Shapiro DJ, Hersh AL, Copp HL. Antibiotic resistance patterns of outpatient pediatric urinary tract infections. J Urol 2013; 190(1):222–7.
Saeed CH, AL-Otraqchi KI, Mansoor IY. Prevalence of urinary tract infections and antibiotics susceptibility pattern among infants and young children in Erbil city. Zanco J Med Sci 2015; 19(1):915–22.
Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC Hospital Aligarh, India. Ann Clin Microbiol Antimicrob 2007; 6(1):4.
Polse RF, Yousif SY, Assafi MS. Prevalence and antimicrobial susceptibility patterns of uropathogenic E. coli among people in Zakho, Iraq. Int J Res Med Sci 2016; 4(4):1219–23.
Salm S, Allen D, Nester E, Anderson D. Nester’s Microbiology: A Human Perspective. 8th ed. New York: Mc Graw Hill Education; 2015. P. 897.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).